Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression

Since amyotrophic lateral sclerosis cases exhibit significant heterogeneity, we aim to investigate the association of lipid composition of plasma and CSF with amyotrophic lateral sclerosis diagnosis, its progression and clinical characteristics. Lipidome analyses would help to stratify patients on a...

Descripción completa

Detalles Bibliográficos
Autores: Sol, Joaquim, Jové, Mariona, Povedano Panades, Mónica, Sproviero, William, Domínguez, Raul, Piñol Ripoll, Gerard, Romero Guevara, Ricardo, Hye, Abdul, Al-Chalabi, Ammar, Torres, Pascual, Andres Benito, Pol, Area Gómez, Estela, Pamplona, Reinald, Ferrer, Isidro (Ferrer Abizanda), Ayala, Victòria, Portero-Otin, Manuel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/182761
Acceso en línea:https://hdl.handle.net/2445/182761
Access Level:acceso abierto
Palabra clave:Esclerosi lateral amiotròfica
Pronòstic mèdic
Líquid cefalorraquidi
Lípids de la sang
Amyotrophic lateral sclerosis
Prognosis
Cerebrospinal fluid
Blood lipids
id ES_2f8fa9dc7dc5bf85eb1d154ca25efaa2
oai_identifier_str oai:diposit.ub.edu:2445/182761
network_acronym_str ES
network_name_str España
repository_id_str
spelling Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progressionSol, JoaquimJové, MarionaPovedano Panades, MónicaSproviero, WilliamDomínguez, RaulPiñol Ripoll, GerardRomero Guevara, RicardoHye, AbdulAl-Chalabi, AmmarTorres, PascualAndres Benito, PolArea Gómez, EstelaPamplona, ReinaldFerrer, Isidro (Ferrer Abizanda)Ayala, VictòriaPortero-Otin, ManuelEsclerosi lateral amiotròficaPronòstic mèdicLíquid cefalorraquidiLípids de la sangAmyotrophic lateral sclerosisPrognosisCerebrospinal fluidBlood lipidsSince amyotrophic lateral sclerosis cases exhibit significant heterogeneity, we aim to investigate the association of lipid composition of plasma and CSF with amyotrophic lateral sclerosis diagnosis, its progression and clinical characteristics. Lipidome analyses would help to stratify patients on a molecular basis. For this reason, we have analysed the lipid composition of paired plasma and CSF samples from amyotrophic lateral sclerosis cases and age-matched non-amyotrophic lateral sclerosis individuals (controls) by comprehensive liquid chromatography coupled to mass spectrometry. The concentrations of neurofilament light chain-an index of neuronal damage-were also quantified in CSF samples and plasma. Amyotrophic lateral sclerosis versus control comparison, in a moderate stringency mode, showed that plasma from cases contains more differential lipids (n = 122 for raw P < 0.05; n = 27 for P < 0.01) than CSF (n = 17 for raw P < 0.05; n = 4 for P < 0.01), with almost no overlapping differential species, mainly characterized by an increased content of triacylglyceride species in plasma and decreased in CSF. Of note, false discovery rate correction indicated that one of the CSF lipids (monoacylglycerol 18:0) had high statistic robustness (false discovery rate-P < 0.01). Plasma lipidomes also varied significantly with the main involvement at onset (bulbar, spinal or respiratory). Notably, faster progression cases showed particular lipidome fingerprints, featured by decreased triacylclycerides and specific phospholipids in plasma, with 11 lipids with false discovery rate-P < 0.1 (n = 56 lipids in plasma for raw P < 0.01). Lipid species associated with progression rate clustered in a relatively low number of metabolic pathways, mainly triacylglyceride metabolism and glycerophospholipid and sphingolipid biosynthesis. A specific triacylglyceride (68:12), correlated with neurofilament content (r = 0.8, P < 0.008). Thus, the present findings suggest that systemic hypermetabolism-potentially sustained by increased triacylglyceride content-and CNS alterations of specific lipid pathways could be associated as modifiers of disease progression. Furthermore, these results confirm biochemical lipid heterogeneity in amyotrophic lateral sclerosis with different presentations and progression, suggesting the use of specific lipid species as potential disease classifiers.Oxford University Press (OUP)2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/182761Articles publicats en revistes (Patologia i Terapèutica Experimental)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1093/braincomms/fcab143Brain Communications, 2021, vol. 3, num. 3https://doi.org/10.1093/braincomms/fcab143cc by (c) Sol, Joaquim et al., 2021http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/1827612026-05-27T06:46:51Z
dc.title.none.fl_str_mv Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
title Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
spellingShingle Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
Sol, Joaquim
Esclerosi lateral amiotròfica
Pronòstic mèdic
Líquid cefalorraquidi
Lípids de la sang
Amyotrophic lateral sclerosis
Prognosis
Cerebrospinal fluid
Blood lipids
title_short Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
title_full Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
title_fullStr Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
title_full_unstemmed Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
title_sort Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression
dc.creator.none.fl_str_mv Sol, Joaquim
Jové, Mariona
Povedano Panades, Mónica
Sproviero, William
Domínguez, Raul
Piñol Ripoll, Gerard
Romero Guevara, Ricardo
Hye, Abdul
Al-Chalabi, Ammar
Torres, Pascual
Andres Benito, Pol
Area Gómez, Estela
Pamplona, Reinald
Ferrer, Isidro (Ferrer Abizanda)
Ayala, Victòria
Portero-Otin, Manuel
author Sol, Joaquim
author_facet Sol, Joaquim
Jové, Mariona
Povedano Panades, Mónica
Sproviero, William
Domínguez, Raul
Piñol Ripoll, Gerard
Romero Guevara, Ricardo
Hye, Abdul
Al-Chalabi, Ammar
Torres, Pascual
Andres Benito, Pol
Area Gómez, Estela
Pamplona, Reinald
Ferrer, Isidro (Ferrer Abizanda)
Ayala, Victòria
Portero-Otin, Manuel
author_role author
author2 Jové, Mariona
Povedano Panades, Mónica
Sproviero, William
Domínguez, Raul
Piñol Ripoll, Gerard
Romero Guevara, Ricardo
Hye, Abdul
Al-Chalabi, Ammar
Torres, Pascual
Andres Benito, Pol
Area Gómez, Estela
Pamplona, Reinald
Ferrer, Isidro (Ferrer Abizanda)
Ayala, Victòria
Portero-Otin, Manuel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Esclerosi lateral amiotròfica
Pronòstic mèdic
Líquid cefalorraquidi
Lípids de la sang
Amyotrophic lateral sclerosis
Prognosis
Cerebrospinal fluid
Blood lipids
topic Esclerosi lateral amiotròfica
Pronòstic mèdic
Líquid cefalorraquidi
Lípids de la sang
Amyotrophic lateral sclerosis
Prognosis
Cerebrospinal fluid
Blood lipids
description Since amyotrophic lateral sclerosis cases exhibit significant heterogeneity, we aim to investigate the association of lipid composition of plasma and CSF with amyotrophic lateral sclerosis diagnosis, its progression and clinical characteristics. Lipidome analyses would help to stratify patients on a molecular basis. For this reason, we have analysed the lipid composition of paired plasma and CSF samples from amyotrophic lateral sclerosis cases and age-matched non-amyotrophic lateral sclerosis individuals (controls) by comprehensive liquid chromatography coupled to mass spectrometry. The concentrations of neurofilament light chain-an index of neuronal damage-were also quantified in CSF samples and plasma. Amyotrophic lateral sclerosis versus control comparison, in a moderate stringency mode, showed that plasma from cases contains more differential lipids (n = 122 for raw P < 0.05; n = 27 for P < 0.01) than CSF (n = 17 for raw P < 0.05; n = 4 for P < 0.01), with almost no overlapping differential species, mainly characterized by an increased content of triacylglyceride species in plasma and decreased in CSF. Of note, false discovery rate correction indicated that one of the CSF lipids (monoacylglycerol 18:0) had high statistic robustness (false discovery rate-P < 0.01). Plasma lipidomes also varied significantly with the main involvement at onset (bulbar, spinal or respiratory). Notably, faster progression cases showed particular lipidome fingerprints, featured by decreased triacylclycerides and specific phospholipids in plasma, with 11 lipids with false discovery rate-P < 0.1 (n = 56 lipids in plasma for raw P < 0.01). Lipid species associated with progression rate clustered in a relatively low number of metabolic pathways, mainly triacylglyceride metabolism and glycerophospholipid and sphingolipid biosynthesis. A specific triacylglyceride (68:12), correlated with neurofilament content (r = 0.8, P < 0.008). Thus, the present findings suggest that systemic hypermetabolism-potentially sustained by increased triacylglyceride content-and CNS alterations of specific lipid pathways could be associated as modifiers of disease progression. Furthermore, these results confirm biochemical lipid heterogeneity in amyotrophic lateral sclerosis with different presentations and progression, suggesting the use of specific lipid species as potential disease classifiers.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/182761
url https://hdl.handle.net/2445/182761
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1093/braincomms/fcab143
Brain Communications, 2021, vol. 3, num. 3
https://doi.org/10.1093/braincomms/fcab143
dc.rights.none.fl_str_mv cc by (c) Sol, Joaquim et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Sol, Joaquim et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Oxford University Press (OUP)
publisher.none.fl_str_mv Oxford University Press (OUP)
dc.source.none.fl_str_mv Articles publicats en revistes (Patologia i Terapèutica Experimental)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405486276673536
score 15,300719

Similares en LA Referencia